K-numberK250541
Device nameSelf-Forming Magnet (Flexagon Plus OTOLoc)
ApplicantGI Windows, Inc.
Product codeSAH
Device classClass II
Decision dateAug 1, 2025
DecisionSubstantially Equivalent
Regulation878.4816
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Flexagon Plus OTOLoc System is a magnetic compression anastomosis device used to create side-to-side connections between small bowel segments (jejunum-to-jejunum or ileum-to-ileum) during minimally invasive laparoscopic surgery. The device uses self-forming magnets that align due to opposing polarity, compress tissue to create the connection, and are naturally expelled from the body in 3-6 weeks once the anastomosis is healed. It is intended for adult patients over 21 years old.

Technological characteristics

The Flexagon Plus OTOLoc maintains identical magnetic strength to the cleared predicate Flexagon SFM, as the self-forming magnets are unchanged. The key addition is the OTOLoc component, which preserves the enterotomy (opening) to permit immediate fluid flow through the intestinal lumen upon implantation—a feature already established in other cleared devices like Valtrac and the NiTi Compression Anastomosis Clip. The alternating dipoles prevent improper apposition while allowing the body to control healing timing.

Test standards cited

ISO 10993 series (cytotoxicity, sensitization, irritation, acute/chronic toxicity, genotoxicity, implantation); ISO 11137-1:2006 and EN ISO 11137-1:2015 (radiation sterilization validation); ASTM D 4169:2022 (transportation and shipping); ISO 10993-18 and ISO 10993-17 (chemical characterization and leachable substance limits).

Substantial equivalence argument

The device is substantially equivalent because it performs the same surgical function using the same magnetic compression technology as the primary predicate (Flexagon SFM, K243482) with identical magnetic strength and intended use. The OTOLoc feature—enabling immediate luminal flow—replicates functionality already cleared in predicate devices Valtrac and NiTi CAC. Performance testing using identical methods to the predicate shows the device meets or exceeds safety and effectiveness benchmarks, with clinical data from 84 patients demonstrating no anastomotic leakage, bleeding, obstruction, or deaths—performance at least as safe as commercially available devices and the predicate.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →